Determinants of primaquine and carboxyprimaquine exposures in children and adults with *Plasmodium vivax* malaria

Running title: **Primaquine exposures in vivax malaria**

Cindy S Chu[1,2], James A Watson[2,3,*], Aung Pyae Phyo[1], Htun Htun Win[1], Widi Yotyingaphiram[1], Suradet Thinraow[1], Nay Lin Soe[1], Aye Aye Aung[1], Pornpimon Wilaisrisak[1], Kanokpich Puaprasert[4], Mallika Imwong[4], Warunee Hanpithakpong[3], Daniel Blessborn[2,3], Joel Tarning[2,3], Stéphane Proux[1], Clare Ling[1,2], Francois H Nosten[1,2], Nicholas J White[2,3]

[1] Shoklo Malaria Research Unit, Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand

[2] Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

[3] Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

[4] Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Keywords: *Plasmodium vivax*, primaquine, pharmacokinetics, relapse, chloroquine, dihydroartemisinin-piperaquine

Corresponding author: james@tropmedres.ac

Abstract

Background

Primaquine is the only widely available drug for radical cure of *Plasmodium vivax* malaria. There is uncertainty whether the pharmacokinetic properties of primaquine are altered significantly in childhood or not.

Methods

Glucose-6-phosphate dehydrogenase normal patients with uncomplicated *P. vivax* malaria were randomized to receive either chloroquine (25mg base/kg) or dihydroartemisinin-piperaquine (dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine; plus either 0.5 mg base/kg/day for 14 days or 1 mg/kg/day for 7 days. Pre-dose day 7 venous plasma concentrations of chloroquine, desethylchloroquine, piperaquine, primaquine and carboxyprimaquine were measured. Methemoglobin levels were measured on days 1, 4, 7.

Results

Day 7 primaquine and carboxyprimaquine concentrations were available for 641 patients. After adjustment for the primaquine mg/kg daily dose, day of sampling, partner drug, and fever clearance, there was a significant non-linear relationship between age and trough primaquine and carboxyprimaquine concentrations, and day methemoglobin levels. Compared to adults 30 years of age, children 5 years of age had trough primaquine concentrations 0.55 (95% CI: 0.39-0.78) fold lower, trough carboxyprimaquine concentrations 0.43 (95% CI: 0.34- 0.55) fold lower, and day 7 methemoglobin levels 0.87 (95% CI: 0.58-1.27) fold lower. Increasing concentrations of piperaquine and chloroquine and poor metabolizer *CYP 2D6* alleles were also associated with

higher day 7 primaquine and carboxyprimaquine concentrations. Increased methemoglobin concentrations were associated with a lower risk of recurrence.

Conclusion

Young children have lower primaquine and carboxyprimaquine exposures, and lower levels of methemoglobinemia, than adults. Young children may need higher weight adjusted primaquine doses than adults.

Introduction

Primaquine is used both for radical cure of *Plasmodium vivax* and *Plasmodium ovale* malaria and as a single dose gametocytocide in *Plasmodium falciparum* malaria (1). Although the slowly eliminated 8-aminoquinoline tafenoquine has been registered in a few countries for use in adults, primaquine is by far the most widely used drug in this class. There is uncertainty whether or not children have lower exposures to primaquine and its bioactive metabolites than adults for the same weight adjusted doses, and thus whether they should receive higher doses than currently recommended (2–5). Primaquine is combined with either an artemisinin combination treatment (ACT) or chloroquine to prevent relapse of vivax or ovale malaria (radical cure) (1). Primaquine is a pro-drug requiring metabolism to bioactive metabolites mainly via the liver cytochrome P450 isoenzyme *CYP 2D6* (6). The prevalence of intermediate and non-functioning *CYP 2D6* alleles is over 50% in some populations, particularly in Asians (7–9). Decreased *CYP 2D6* function, resulting from intermediate or poor metabolizer genotypes, potentially lowers radical cure efficacy (10, 11).

Chloroquine has been the first-line treatment for the blood stages of *P. vivax* malaria for over 70 years (1). High grade resistance remains confined to Oceania and Indonesia (12) but, in the last decade, low grade chloroquine resistance, manifest by earlier appearance of relapses, has been reported increasingly in other locations. Piperaquine (a slowly eliminated bisquinoline), combined with dihydroartemisinin, is a well-tolerated and highly efficacious ACT which provides an excellent alternative blood stage treatment for *P. vivax* malaria (13). This open label two-way randomized controlled trial conducted on the Thailand-Myanmar border showed previously that a 7-day high dose primaquine regimen (1 mg/kg/day) , combined either with chloroquine or

73 dihydroartemisinin-piperaquine, was non-inferior to the standard 14-day (0.5 mg/kg/day)
74 regimen (14). This study allowed investigation of the pharmacokinetic properties of primaquine
75 in adults and children, characterization of the determinants of drug exposures, and correlation
76 with therapeutic outcomes.

77 ## Methods

78 ### Clinical trial

79 This study was conducted by the Shoklo Malaria Research Unit (SMRU), which is located on the
80 northwest Thailand-Myanmar border. Full details of the study have been reported previously
81 (14). In brief, patients who presented to an outpatient clinic with microscopy confirmed
82 uncomplicated *P. vivax* mono-infections were enrolled if they were ≥ 6 months old, and if they
83 were glucose-6-phosphate dehydrogenase (G6PD) normal by the fluorescent spot test. Patients
84 were excluded if they were pregnant or breastfeeding an infant ≤ 6 months, had a hematocrit
85 ≤25%, or received a blood transfusion within 3 months. Written informed consent was obtained
86 from patients or from parents or carers of children below 18 years old.
87 Patients were randomized 1:1:1:1 to each of the following groups:

88 1. Chloroquine (10 mg base/kg on the first two days of treatment, then 5 mg base/kg on day
89 3; Remedica, Ltd., Cyprus) and primaquine (1 mg base/kg/day for 7 days; Government
90 Pharmaceutical Organization, Thailand)
91 2. Chloroquine as above and primaquine (0.5 mg base/kg/day for 14 days)
92 3. Dihydroartemisinin-piperaquine (dihydroartemisinin 7 mg/kg and piperaquine 55 mg/kg
93 for 3 days; Guilin Pharmaceutical company, China) and primaquine (1 mg base/kg/day for

94 7 days)

95 4. Dihydroartemisinin-piperaquine as above plus primaquine (0.5 mg base/kg/day for 14

96 days)

97 Food and drink were given before drug administration. Patients were assessed daily while on

98 treatment. Methemoglobin was measured either daily or on days 1, 3, 6 and 13, and additionally

99 on day 10 in the primaquine 14-day groups, using a transcutaneous pulse oximeter (Masimo

100 Radical-7®). One recruitment clinic did not have access to a transcutaneous oximeter, so 80

101 study patients did not have methemoglobin measurements. All drug doses were supervised.

102 A venous blood sample for antimalarial drug levels was taken before drug administration on day

103 6 (the 7th day of treatment) +/- 2 days, and plasma was separated. Patients were followed at

104 weeks 2 and 4, and then every 4 weeks until 52 weeks. If there was a *P. vivax* recurrence then a

105 venous plasma blood sample for drug levels was taken again. Standard high dose primaquine (0.5

106 mg/kg/day for 14 days) and chloroquine were given for the treatment of recurrences. Follow-up

107 was re-started as if newly recruited and day 6 sampling for drug levels was collected again. The

108 total study duration was 52 weeks from enrolment.

109 Drug measurements

110 Chloroquine/desethylchloroquine, piperaquine, and primaquine/carboxyprimaquine plasma

111 concentrations were measured using three validated liquid chromatography (LC) – tandem mass

112 spectrometry (MS/MS) methods (15–17). The lower limits of quantification (LLOQ) were set to

113 1.4, 1.5, 1.14 and 4.88 ng/mL for chloroquine/desethylchloroquine, piperaquine, primaquine and

114 carboxyprimaquine, respectively. All three quantification methods were validated according to

115 regulatory standards and three levels of quality control samples were analyzed in triplicate within

116 each batch of clinical samples. Total imprecision (i.e. relative standard deviation) for all quality
117 control samples was below 10% during drug quantification.

118 *CYP 2D6* genotyping

119 We carried out a nested case-control study to assess the effect of *CYP 2D6* polymorphisms on
120 recurrent vivax malaria. Cases were all patients with a recorded recurrent episode of vivax
121 malaria during follow-up and controls were a set of patients matched by age and sex (total of
122 n=154 patients). The *CYP 2D6* gene duplications/multiplications and gene deletions were
123 determined by extra-long range polymerase chain reaction (XL-PCR) using a previously published
124 protocol (18). The functional *CYP 2D6* and nonfunctional *CYP2D8* and *CYP2D7* genes were then
125 differentiated by intron 2 sequencing (INT2). For a subset of samples, the variants *2, *4, *5, *10,
126 *35, and *36 were identified with rapid identification of four polymorphic loci by allele-specific
127 oligonucleotide probes using real-time SNPs genotyping. From the *CYP 2D6* genotyping result the
128 *CYP 2D6* activity score was obtained (15, 19–21).

129 Ethics approval

130 This study was approved by both the Mahidol University Faculty of Tropical Medicine Ethics
131 Committee (MUTM 2011-043, TMEC 11-008) and the Oxford Tropical Research Ethics
132 Committee (OXTREC 17-11) and was registered at ClinicalTrials.gov (NCT01640574).

133 Statistical analysis

134 All drug concentrations were analyzed on the log base 10 scale. Three main generalized additive
135 linear regression models were fitted to the $\log_{10}$ primaquine day 7 concentrations; the $\log_{10}$
136 carboxyprimaquine concentrations; and the $\log_{10}$ carboxyprimaquine to primaquine ratios. We

137 used the following predictors age (years), mg/kg daily dose of primaquine, study arm (DHA-
138 piperaquine versus chloroquine), fever clearance time (days), and days since start of primaquine
139 dosing (6 versus 4). A smooth spline term with 3 degrees of freedom was used to estimate non-
140 linear effects of age. Individual random intercept terms were specified to account for multiple
141 day 7 measurements in the same patient. To assess any residual effect of *CYP 2D6* diplotypes, we
142 fitted linear regression models to the model residual concentrations with the *CYP 2D6* activity
143 score as a linear predictor. To estimate the effect of the partner drug concentrations (not
144 available for every day 7 measurement), we fitted separate generalized additive regression
145 models to the primaquine and carboxyprimaquine $\log_{10}$ concentrations with either the $\log_{10}$
146 chloroquine+desethychloroquine (designated as 'chloroquine' in the remainder of the paper)
147 concentration or the $\log_{10}$ piperaquine concentration as additional predictors.
148 We fitted a generalized additive regression model to the day 7 blood methemoglobin
149 concentrations (expressed as a percentage of the hemoglobin concentration) with age, mg/kg
150 daily dose of primaquine, study arm (DHA-piperaquine versus chloroquine), fever clearance time
151 (days), and days since start of primaquine dosing as predictors. A spline term with 3 degrees of
152 freedom was fit to age. Secondary models included the *CYP 2D6* activity score (available only for
153 a subset of patients) as an additional covariate, both on the linear scale and as a binary covariate
154 ($\leq$0.5 versus >0.5). The activity score has an arbitrary scale so it is unclear how best to encode it
155 in regression models (i.e. an activity score of 2 versus 1 is not the same as 1 versus 0).
156 We fitted Cox proportional hazard models to the time to first recurrence (right censored event
157 for patients who did not have a recurrence during follow-up), with continuous predictors: age,
158 partner schizonticidal drug (chloroquine versus piperaquine), and either the $\log_{10}$ primaquine or

159 the $\log_{10}$ carboxyprimaquine day 7 concentration (they are highly co-linear so we fitted two
160 separate models). Additional models included the day 7 methemoglobin levels as an additional
161 predictor (this was not measured in all patients).
162 The generalized additive models were fitted in R version 4.0.2 using the package *mgcv* version
163 1.8. The Cox proportional hazard model used the *survival* package version 3.2. Code in the form
164 of an RMarkdown script along with all analyzed data are available on an accompanying github
165 repository for full reproducibility (https://github.com/jwatowatson/Primaquine_day7).

166 **Results**

167 Between February 2012 and July 2014, 680 patients with uncomplicated acute *P. vivax* malaria
168 were enrolled. A total of 641 patients had at least one day 7 plasma primaquine and
169 carboxyprimaquine concentration measured, either during the enrollment episode or during a
170 recurrent *P. vivax* episode (there were a total of 720 episodes with day 7 concentrations including
171 patients with multiple episodes). For 692 of these day 7 concentrations, the corresponding
172 plasma chloroquine or piperaquine concentration was also available (measured from the same
173 blood sample). We excluded three drug measurements from three patients who stopped
174 primaquine before day 7 (resulting in a total of 717 day 7 measurements included in the analysis).
175 In total, 71 of the patients with measured primaquine and carboxyprimaquine concentrations
176 were 6 to ≤10 years of age (median weight 20kg, range 13-30kg), and 34 were ≤5 years of age
177 (median weight 14kg, range 8-20kg) (Table 1). Three patients were less than 3 years old, and the
178 youngest was 1 year 6 months old. Fever and parasite clearance were similar across all age
179 groups. The proportion of patients with microscopy detected gametocytemia was higher in the
180 older age groups >10 years.

181 Effect of age

182 After adjustment for the daily mg/kg primaquine dose, the number of days of dosing, the fever
183 clearance times, and the partner drug (piperaquine versus chloroquine), there was a significant
184 non-linear association between age and day 7 primaquine trough concentration ($p=10^{-9}$ for the
185 smooth spline term fit to age) and day 7 carboxyprimaquine trough concentration ($p=10^{-29}$ for
186 the smooth spline term fit to age) (Figure 1). For both primaquine and carboxyprimaquine,
187 increasing age was correlated with higher trough levels. The strongest effect was seen for the
188 carboxyprimaquine trough levels. The ratio of carboxyprimaquine to primaquine was thus also
189 associated with age, with an approximate doubling when comparing patients aged $\leq$5 years
190 versus patients 30 years or older (Figure 1).

191 Effect of partner drug

192 Previously healthy volunteer studies reported that co-administration of piperaquine and
193 chloroquine both increased exposures to primaquine and carboxyprimaquine (15, 16, 22). In this
194 study of patients with vivax malaria, a ten-fold increase in the chloroquine day 7 concentration
195 was associated with a 2.2 fold increase in day 7 primaquine concentrations (95% CI: 1.7 to 2.9;
196 $p=0.004$), and a 1.8 fold increase in day 7 carboxyprimaquine concentration (95% CI: 1.5 to 2.2;
197 $p=0.001$). A ten-fold increase in the piperaquine day 7 concentration was associated with a 2.5
198 fold increase in primaquine concentration (95% CI: 1.9 to 3.3; p=0.0008), and a 2.7 fold increase
199 in carboxyprimaquine concentration on day 7 (95% CI: 2.2 to 3.3; $p=10^{-7}$). For both chloroquine
200 and piperaquine, there was no statistically significant effect on the
201 carboxyprimaquine/primaquine ratios.

202 Effect of *CYP 2D6* genotypes

203 *CYP 2D6* genotypes were determined in 154 patients. The estimated *CYP 2D6* allele frequencies
204 in this population were as follows: 25% for *1; 23% for *2; 2% for *4; 10% for *5; 38% for *10;
205 0.5% for *39; and 1% for *36. Alleles *4, *5, and *36 are considered null-metabolizer alleles
206 (activity score of 0); *10 is a poor metabolizer allele (activity score of 0.25); and *1 and *39 are
207 normal metabolizer alleles (activity score of 1). In total, there were 3 patients with an activity
208 score of 0 (non-metabolizers) and 36 patients with activity scores of either 0.25 or 0.5 (poor
209 metabolizers). For primaquine day 7 plasma concentrations, model residuals (defined as the
210 observed concentration minus the predicted concentration, both on the log scale where the
211 model is based on age, mg/kg dose and partner drug), were significantly associated with the
212 genotype-defined *CYP 2D6* enzyme activity scores (Figure 2; p=0.001). Patients with low *CYP 2D6*
213 activity scores had, on average, higher observed concentrations of primaquine than predicted
214 (i.e. positive residuals), whereas patients with normal activity scores had lower concentrations
215 than expected (i.e. negative residuals). For plasma carboxyprimaquine concentrations, a trend in
216 the same direction was observed but the effect was substantially smaller and was not significant
217 (p=0.1).

218 Methemoglobinemia and hemolysis

219 Primaquine causes predictable methemoglobinemia. As reported previously methemoglobin
220 concentrations rose over the first week of primaquine treatment, and then plateaued in the 14-
221 day primaquine groups. The day 7 values were usually the peak recorded values
222 (Supplementary Figure 1). Methemoglobin (expressed as a percentage of the hemoglobin
223 concentration) was lower in children than in young adults ($p<10^{-16}$ for a spline term fit to age in

224 a generalized additive regression model, Figure 3A), and was lower in patients with loss of
225 function *CYP 2D6* polymorphisms (absolute decrease of 1.2 percentage points in the mean day
226 7 methemoglobin level in patients with an activity score ≤ 0.5 compared to patients with an
227 activity score > 0.5; 95% CI: 0.1-2.3%, *p*=0.04). Day 7 methemoglobin levels were associated
228 with both primaquine and carboxyprimaquine day 7 plasma concentrations. A ten-fold increase
229 in primaquine day 7 concentration was associated with an absolute increase of 0.7 percentage
230 points in day 7 methemoglobin (95% CI: 0.14-1.23), and a ten-fold increase in
231 carboxyprimaquine concentration was associated with an absolute increase of 1.2 percentage
232 points in day 7 methemoglobin levels (95% CI: 0.5 – 2.0). Four patients stopped primaquine
233 because of elevated methemoglobin levels and associated symptoms. Two of these patients
234 stopped on day 5 and thus had low day 7 primaquine and carboxyprimaquine levels as the day
235 6 primaquine dose was not administered. One of these patients had a recorded methemoglobin
236 level of 20.9% on day 6 followed by 18.1% on day 7. The other three patients had peri-oral
237 cyanosis (blue lips). Their peak recorded methemoglobin levels were between 10 and 12%.
238 There was no relationship between age and hemolysis defined as the percentage drop in
239 hematocrit between baseline and day 7 (Figure 3B).

240 Primaquine exposure and *P. vivax* recurrence

241 We did an exploratory analysis of the relationship between primaquine exposures and times to
242 the first *P. vivax* recurrence. A total of 564 patients had recorded day 7 drug levels and
243 methemoglobin levels, and 70 had at least one recurrence during follow-up. After adjusting for
244 age and partner drug, day 7 concentrations of primaquine and carboxyprimaquine were not
245 associated with the risk of recurrence, but a 1% absolute increase in day 7 methemoglobin was

246 associated with a hazard ratio for recurrence of 0.9 (95% CI: 0.85-0.99, p=0.02). Two of the
247 three patients with a *CYP 3D6* activity score of 0 had a *P. vivax* recurrence, and one of them had
248 2 recurrences (the interval between recurrences was >65 days).

249 **Discussion**

250 Radical cure of *P. vivax* malaria is necessary to prevent relapses. Relapses are a major cause of
251 morbidity and developmental delay in children living in endemic areas, so optimization of dosing
252 is critical in this population. The higher *P. vivax* relapse rates in children compared with adults
253 living in endemic areas observed in some studies (23) are attributed usually to lower levels of
254 immunity, but lower drug exposures could also be a contributory factor. For many antimalarial
255 drugs, exposures in children are lower than in adults and an increase in the weight adjusted
256 dosing is needed (1). The limited pharmacokinetic evidence to date for primaquine does not
257 provide a clear picture, with a study from Papua New Guinea suggesting little difference between
258 adults and older children (2), whereas a study of single dose primaquine (used as a *P. falciparum*
259 gametocytocide) in Tanzania (3) and a study of primaquine for *P. vivax* radical cure in Brazil (4)
260 both suggested that younger children had lower exposures. Primaquine is metabolized rapidly
261 (elimination half-life ~5 hours) via monoamine oxidase to a biologically inert metabolite
262 carboxyprimaquine and, through a separate pathway, to several active hydroxylated metabolites
263 mainly via *CYP 2D6* (6, 24). Recent laboratory studies suggest that these unstable hydroxylated
264 metabolites are oxidized to quinoneimines generating local hydrogen peroxide - which is
265 parasiticidal. The quinoneimines in turn are substrates for cytochrome P450
266 NADPH:oxidoreductase (POR or CPR) resulting in hydrogen peroxide accumulation and
267 augmenting the parasiticidal effect (25). These reactions mediate the antimalarial therapeutic

268 effects, and also the oxidant hemolytic adverse effects. There is also evidence for synergy
269 between the 8-aminoquinolines and other quinoline antimalarials in blood stage activity (26, 27).
270 The 8-aminoquinolines have innate schizonticidal activity as well as in radical curative activity and
271 4-aminoquinoline antimalarials increase primaquine concentrations (15, 16). Unfortunately,
272 although the metabolic pathway to the production of the active primaquine metabolites has
273 been characterized ex-vivo, no validated measure of their concentrations, or of their more stable
274 metabolites, in whole blood, plasma, or urine has yet been correlated with antimalarial
275 therapeutic responses in-vivo. Thus, measurement of primaquine and carboxyprimaquine
276 concentrations does not provide a direct correlate of antimalarial activity. Furthermore, because
277 the apparent volume of distribution of carboxyprimaquine is not known, the proportion of parent
278 drug that passes through this inactive metabolic pathway cannot be estimated.
279
280 This large study of day 7 “trough” primaquine and carboxyprimaquine plasma concentrations
281 shows clearly that exposures to both parent compound and inactive metabolite are lower in
282 children than in adults. This is unlikely to be explained by lower bioavailability as primaquine is
283 generally well absorbed, the children in the study were clinically well by seven days after starting
284 treatment (14), all doses were observed and only 7 children ≤10 years old (≤27kg) vomited. It
285 presumably reflects either larger primaquine (and carboxyprimaquine) distribution volumes, or
286 increased clearance, or both. The lower ratio of carboxyprimaquine to primaquine in children
287 may also be explained by these age-related pharmacokinetic changes. Although a greater
288 diversion down the bioactive CYP pathway cannot be excluded - there is no convincing evidence
289 for augmented drug efficacy (no relationship with fever or parasite clearance time) or increased

290 hemolytic toxicity in children to support this. Furthermore, in this study, methemoglobinemia
291 was lower in children than in young adults, indicating that formation of oxidant metabolites was
292 reduced (28). The importance of *CYP 2D6* primaquine bioactivation in the generation of oxidant
293 metabolites was evidenced by the lower levels of methemoglobinemia in patients with loss of
294 function *CYP 2D6* polymorphisms. Together this evidence strongly suggests that children have
295 lower exposures to the biologically active metabolites of primaquine than do adults receiving the
296 same weight adjusted doses.
297
298 This study was sufficiently large that the influence of other covariates affecting primaquine
299 exposures could be examined. We have reported previously that co-administration of quinoline
300 or structurally related antimalarials increases primaquine and carboxyprimaquine concentrations
301 (15, 16). This was confirmed in this study. The effects on the parent compound of chloroquine
302 and piperaquine were similar whereas piperaquine had a larger effect on carboxyprimaquine. In
303 Asia loss of function *CYP 2D6* genetic polymorphisms (mainly the *10 allele) are common. In this
304 study low *CYP 2D6* activity scores (derived from the genotype) were associated with higher
305 primaquine levels and lower levels of methemoglobinemia as would be expected from reduced
306 metabolic conversion through this bioactivation pathway.
307 There are several limitations to this study. This analysis is limited to drug concentrations at one
308 time point during radical cure treatment providing a limited description of drug exposures. Very
309 young children are under-represented, and the analysis does not include any infants < 1 year old.
310 In addition, *CYP 2D6* genotyping was not performed in all patients.

311 There is no evidence that the adverse effects of primaquine are significantly worse in children
312 than adults. The main therapeutic implication of this large pharmacometric evaluation is that
313 children may require larger weight adjusted doses of primaquine than adults.

314 Funding

315 This work was supported by the Wellcome Trust [grant number 089179/Z/09/Z] to NJW. CSC, JW,
316 APP, JT, CL, FHN and NJW are supported by the Wellcome Trust [Programme grant number
317 089179]. CSC, JW, APP, JT, CL, FHN, and NJW are part of the Wellcome Trust Mahidol University
318 Oxford Tropical Medicine Research Programme funded by the Wellcome Trust.

319

320 Acknowledgements

321 This research was funded by The Wellcome Trust. A CC BY or equivalent license is applied to the
322 author accepted manuscript arising from this submission, in accordance with the grant's open
323 access conditions. The authors would like to thank the SMRU staff for their hard work in
324 running this study and the MORU Clinical Pharmacology Laboratory in Bangkok for their diligent
325 work in sample processing and drug measurements. Special appreciation goes to the
326 contributions of Htet Htet Chaw, Nwe Wah Lin, Thida Zin, Say Paw, Naw Eh Shee, Thu Lay Paw,
327 Rattanporn Raksapraidee, Moo Koo Paw, the data entry team headed by Jacher
328 Wiladphaingern, the logistics team, and the laboratory teams headed by Kanlaya Sriprawat and
329 Germana Bancone.
330 We would also like to thank the Data Safety and Monitoring Board: Bob Taylor, Charles Woodrow,
331 and Professor Nicholas Day for their time and commitment.

332 **References**

333 1. World Health Organization. 2015. Guidelines for the treatment of malaria, 3rd Edition. World
334 Health Organization, Geneva.

335 2. Moore BR, Salman S, Benjamin J, Page-Sharp M, Robinson LJ, Waita E, Batty KT, Siba P, Mueller I,
336 Davis TME, Betuela I. 2014. Pharmacokinetic properties of single-Dose primaquine in papua new
337 guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.
338 Antimicrob Agents Chemother 58:432–439.

339 3. Gonçalves BP, Pett H, Tiono AB, Murry D. 2017. Age, weight, and CYP2D6 genotype are major
340 determinants of primaquine pharmacokinetics in African children. Antimicrob Agents Chemother
341 Agents Chemother 61:e02590-16.

342 4. Vieira MVDF, Matos Lopes TR, Mello AGNC, de Sena LWP, Commons RJ, Vieira JLF. 2020. Doses of
343 primaquine administered to children with Plasmodium vivax according to an age-based dose
344 regimen. Pathog Glob Health 114:388–392.

345 5. Gogtay N, Karande S, Kadam P, Momin S, Thatte U. 2021. Evaluation of pharmacokinetics of
346 single-dose primaquine in undernourished versus normally nourished children diagnosed with
347 Plasmodium vivax malaria in Mumbai. J Postgrad Med 67:75–79.

348 6. Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard G a,
349 Ockenhouse C, Bennett J, Walker L a, Ohrt C, Melendez V. 2013. The metabolism of primaquine
350 to its active metabolite is dependent on CYP 2D6. Malar J 12:e212.

351 7. Neafsey P, Ginsberg G, Hattis D, Sonawane B. 2009. Genetic polymorphism in cytochrome P450
352 2D6 (CYP2D6): Population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev
353 12:334–361.

354 8. McGraw J, Waller D. 2012. Cytochrome P450 variations in different ethnic populations. Expert
355 Opin Drug Metab Toxicol 8:371–382.

356 9. Puaprasert K, Chu C, Saralamba N, Day NPJ, Nosten F, White NJ, Dondorp AM, Imwong M. 2018.
357 Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen
358 population study. Malar J 17:427.
359 10. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC. 2013. Primaquine failure and cytochrome P-
360 450 2D6 in Plasmodium vivax malaria. N Engl J Med 369:1380–1381.
361 11. Baird JK, Louisa M, Noviyanti R, Ekawati L, Elyazar I, Subekti D, Chand K, Gayatri A, Instiaty,
362 Soebianto S, Crenna-Darusallam C, Djoko D, Hasto BD, Meriyenes D, Wesche D, Nelwan EJ,
363 Sutanto I, Sudoyo H, Setiabudy R. 2018. Association of Impaired Cytochrome P450 2D6 Activity
364 Genotype and Phenotype with Therapeutic Efficacy of Primaquine Treatment for Latent
365 Plasmodium vivax Malaria. JAMA Netw Open 1:e181449.
366 12. Price RN, von Seidlein L, Valecha N, Nosten FH, Baird JK, White NJ. 2014. Global extent of
367 chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis
368 14:982–91.
369 13. Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, Auburn S,
370 Chand K, Chau NH, Cheah PY, Dong LT, Dhorda M, Degaga TS, Devine A, Ekawati LL, Fahmi F,
371 Hailu A, Hasanzai MA, Hien TT, Khu H, Ley B, Lubell Y, Marfurt J, Mohammad H, Moore KA,
372 Naddim MN, Pasaribu AP, Pasaribu S, Promnarate C, Rahim AG, Sirithiranont P, Solomon H,
373 Sudoyo H, Sutanto I, Thanh NV, Tuyet-Trinh NT, Waithira N, Woyessa A, Yamin FY, Dondorp A,
374 Simpson JA, Baird JK, White NJ, Day NP, Price RN. 2019. Short-course primaquine for the radical
375 cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority
376 trial. Lancet 394:929–938.
377 14. Chu CS, Phyo AP, Turner C, Win HH, Poe NP, Yotyingaphiram W, Thinraow S, Wilairisak P,
378 Raksapraidee R, Carrara VI, Paw MK, Wiladphaingern J, Proux S, Bancone G, Sriprawat K, Lee SJ,
379 Jeeyapant A, Watson JA, Tarning J, Imwong M, Nosten F, White NJ. 2018. Chloroquine versus

380 dihydroartemisinin-piperaquine with standard High-dose primaquine given either for 7 days or
381 14 days in Plasmodium vivax malaria. Clin Infect Dis 68:1311–1319.
382 15. Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W,
383 Chotsiri P, Wattanakul T, Panapipat S, Lee SJ, Day NPJ, White NJ. 2014. Open-Label Crossover
384 Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai
385 Subjects. Antimicrob Agents Chemother 58:7340–7346.
386 16. Pukrittayakamee S, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri S, Lee SJ,
387 Hanpithakpong W, Hanboonkunupakarn B, Day NPJ, Ashley E a, White NJ. 2014. Pharmacokinetic
388 interactions between primaquine and chloroquine. Antimicrob Agents Chemother 58:3354–3359.
389 17. Kaewkhao K, Chotivanich K, Winterberg M, Day NP, Tarning J, Blessborn D. 2019. High sensitivity
390 methods to quantify chloroquine and its metabolite in human blood samples using LC-MS/MS.
391 Bioanalysis 11:333–347.
392 18. Dorado P, Cáceres MC, Pozo-Guisado E, Wong ML, Licinio J, LLerena A. 2005. Development of a
393 PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential
394 use. Biotechniques 39:571–574.
395 19. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. 2008. The CYP2D6 activity
396 score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol
397 Ther 83:234–242.
398 20. Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling M V.,
399 Scott SA, Hertz DL, Guchelaar HJ, Gaedigk A. 2020. Standardizing CYP2D6 Genotype to Phenotype
400 Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation
401 Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci 13:116–124.
402 21. Spring MD, Lon C, Sok S, Sea D, Wojnarski M, Chann S, Kuntawunginn W, Heng TK, Nou S,
403 Arsanok M, Sriwichai S, Vanachayangkul P, Lin JT, Manning JE, Jongsakul K, Pichyangkul S,

404 Satharath P, Smith PL, Dysoley L, Saunders DL, Waters NC. 2020. Prevalence of CYP2D6
405 genotypes and predicted phenotypes in a cohort of cambodians at high risk for infections with
406 plasmodium vivax. Am J Trop Med Hyg 103:756–759.
407 22. Lee SJ, McGready RM, Fernandez C, Stepniewska K, Paw MK, Viladpai-Nguen SJ, Thwai KL,
408 Villegas L, Singhasivanon P, Greenwood BM, White NJ, Nosten FH. 2008. Chloroquine
409 pharmacokinetics in pregnant and nonpregnant women with vivax malaria. Eur J Clin Pharmacol
410 64:987–992.
411 23. Luxemburger C, van Vugt M, Jonathan S, McGready RM, Looareesuwan S, White NJ, Nosten FH.
412 1999. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg
413 93:433–438.
414 24. Avula B, Tekwani BL, Chaurasiya ND, Fasinu P, Dhammika Nanayakkara NP, Bhandara Herath
415 HMT, Wang Y-H, Bae J-Y, Khan SI, Elsohly MA, McChesney JD, Zimmerman PA, Khan IA, Walker
416 LA. 2018. Metabolism of primaquine in normal human volunteers: investigation of phase I and
417 phase II metabolites from plasma and urine using ultra-high performance liquid chromatography-
418 quadrupole time-of-flight mass spectrometry. Malar J 17:294.
419 25. Camarda G, Jirawatcharadech P, Priestley RS, Saif A, March S, Wong MHL, Leung S, Miller AB,
420 Baker DA, Alano P, Paine MJI, Bhatia SN, O'Neill PM, Ward SA, Biagini GA. 2019. Antimalarial
421 activity of primaquine operates via a two-step biochemical relay. Nat Commun 10: e3226.
422 26. Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flanagan CL. 1955. Potentiation
423 of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med
424 46: 301-6.
425 27. Baird JK. 2019. 8-Aminoquinoline therapy for latent malaria. Clin Microbiol Rev 32:1–68.
426 28. Umbreit J. 2007. Methemoglobin--it’s not just blue: a concise review. Am J Hematol 82:134–144.
427

428 **Tables and Figures**

429 Table 1. Patient characteristics at enrolment by age group

	Age group			
	≤5 years	6-10 years	11-15 years	≥16 years
	n=34	n=71	n=118	n=418
Chloroquine+Primaquine-7	8 (5%)	22 (13%)	29 (18%)	104 (64%)
Chloroquine+Primaquine-14	10 (6%)	18 (11%)	29 (18%)	103 (65%)
DHAP+Primaquine-7	7 (4%)	15 (10%)	37 (24%)	98 (62%)
DHAP+Primaquine-14	9 (6%)	16 (10%)	23 (14%)	113 (70%)
Median age years (IQR, range)	4 (3.2-5, 1.5-5)	8 (6-10, 5.1-10)	13 (12-14, 11-15)	28 (20-39, 16-63)
Median weight, kg (IQR, range)	14 (12-16, 8-20)	20 (16-23, 13-30)	35 (29-43, 21-57)	52 (47-56, 31-88)
Median Body Mass Index, kg/m^2 (IQR, range)	15 (14-16, 13-18)	14 (14-15, 11-18)	17 (15-18, 12-23)[1]	20 (19-22, 13-36)
History of fever, n (%)	34 (100%)	71 (100%)	118 (100%)	411 (98%)
Median temperature >37.5^{o}C, (IQR, range)	37.5 (36.7-38.2, 36-40)	37.4 (36.8-38.2, 36-40.1)	37.6 (37-38.5, 36-40.9)[1]	37.3 (36.8-38.1, 36-40.9)
Fever clearance; days (range)	0 (0-4)	0 (0-3)	1 (0-2)	0 (0-4)
Geometric mean parasitemia, parasites/µL (range)	3096 (16-40,192)	3633 (16-221,056)	4886 (16-75,109)	3804 (16-816,400)
Parasite clearance, days (range)	2 (1-4)	2 (1-3)	2 (1-4)	2 (1-5)
Gametocytemia, n (%)	23 (68%)	56 (79%)	104 (88%)	352 (84%)
Median chloroquine level[a], ng/mL (range)	54.3 (6.4-115)	50.1 (27.3-138)	56.1 (27.6-161)	77.9 (26.9-248)
Median piperaquine level[a], ng/mL (range)	37.5 (15.3-109)	29.4 (10-7-78.2)	35.3 (7.7-131)	37 (7.3-181)
Median carboxyprimaquine level[a], ng/mL (range)	261 (29-1410)	406 (9-1590)	563 (40-2740)	793 (59-4710)
Median primaquine level[a], ng/mL (range)	3.5 (1.1-43.8)	3.8 (0.9-349)	5.2 (0.9-106)	6.9 (1-293)
Median carboxyprimaquine: primaquine ratio[a], (range)	86 (12-207)	97 (4-256)	98 (23-516)	106 (2-564)

430

431 Primaquine-7: primaquine dosing 1 mg/kg/day for 7 days

432 Primaquine-14: primaquine dosing 0.5 mg/kg/day for 14 days

433 Numeric superscript denotes the number of missing values

434 [a] Only data from the first episode are included

435

436 **Legends to Figures**

437 Figure 1: The effect of age on primaquine and carboxyprimaquine exposures in patients with acute vivax
438 malaria.

439 Panel A: age versus mg/kg primaquine daily dose;

440 Panel B: age versus the primaquine concentration on day 7;

441 Panel C: age versus the carboxyprimaquine concentration on day 7;

442 Panel D: age versus the ratio of the day 7 carboxyprimaquine to primaquine concentration.

443 The black lines show model fits using a generalized additive model with a smooth spline term for age
444 and adjusting for daily mg/kg dose; number of days of primaquine received, partner drug and fever
445 clearance time (dashed: mean predicted concentration for 1mg/kg daily; solid: mean predicted
446 concentration for 0.5 mg/kg daily).

447

448 Figure 2: The effect of *CYP 2D6* genotypes on primaquine and carboxyprimaquine exposure. The y-axis
449 shows the model residuals (observed minus predicted) for the main model of exposure (adjusting for
450 age, daily mg/kg primaquine dose, partner drug, and fever clearance time). The x-axis is the predicted
451 activity score from the *CYP 2D6* diplotype (20) . The thick black lines show a linear regression fit.

452

453 Figure 3: Age and drug exposure relationships with hemolysis and methemoglobinemia.

454 Panel A: Age and day 7 methemoglobin

455 Panel B: Age and the day 7 change in hematocrit from baseline.

456 Panel C: Day 7 methemoglobin and pre-dose primaquine concentrations

457 Panel D: Day 7 methemoglobin and pre-dose carboxyprimaquine concentrations

458

459 Supplementary Figure 1: Methemoglobin as function of the time since starting primaquine (black

460 circles: 0.5 mg/kg target dose for 14 days; red circles: 1 mg/kg target dose for 7 days). We added

461 random jitter to the time in days for visual clarity.


A
DHA-piperaquine
Chloroquine
Daily dose (mg/kg)
1.4
1.2
1.0
0.8
0.6
0.4
0.2
1.5
3
10
30
Age (years)
B
Primaquine (ng/mL)
316
75
18
4
1
1.5
3
10
30
Age (years)
C
Carboxyprimaquine (ng/mL)
3162
750
178
42
10
1.5
3
10
30
Age (years)
D
Carboxyprimaquine/Primaquine ratio
316
126
50
20
8
3
1.5
3
10
30
Age (years)

Figure 1


Model residual (primaquine)
1.5
1.0
0.5
0.0
-0.5
-1.0
0.0
0.5
1.0
1.5
2.0
CYP 2D6 activity score
Model residual (carboxyprimaquine)
0.5
0.0
-0.5
-1.0
0.0
0.5
1.0
1.5
2.0
CYP 2D6 activity score

Figure 2


A
DHA-piperaquine
Chloroquine
Methemoglobin day 7 (%)
Age (years)
B
Change in haematocrit from baseline (%)
Age (years)
C
Methemoglobin day 7 (%)
Primaquine day 7 (ng/mL)
D
Methemoglobin day 7 (%)
Carboxyprimaquine day 7 (ng/mL)

Figure 3



472

473 Supplementary Figure 1